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Introduction: Building upon the comorbidity between atopy and schizophrenia, we 
conducted a large cross-sectional, observational population-based study to examine 
if such associations also exist between atopic disorders (eczema, allergic rhinitis, and 
asthma) and nonclinical psychotic experiences.
Methods: We examined psychotic experiences in a Dutch population sample through 
an online survey (≥14 years of age). Participants filled out the Questionnaire for Psychotic 
Experiences, together with questions screening for atopic disorders (eczema, allergic 
rhinitis, and asthma). Prevalence rates were calculated; binary logistic regression was 
used to determine odds ratios (ORs) (age, gender, and years of education as covariates).
Results: We included 6,479 participants. Individuals diagnosed with one or more atopic 
disorders had an increased risk of psychotic experiences as compared with controls 
(OR = 1.26). Analysis of individual symptoms revealed an OR of 1.27 for hallucinations, 
whereas delusions only showed a trend. With each additional atopic disorder, the risk of 
psychotic experiences increased. This was also observed for hallucinations alone but not 
for delusions alone. Atopy was associated with hallucinations across all modalities (OR 
ranging from 1.19 to 1.40). These results did not appear to be driven specifically by any 
one of the atopic disorders.
Conclusion: In the largest population sample of adolescents and adults to date, we 
found that atopic disorders (asthma, eczema, and allergic rhinitis) increase the risk of 
psychotic experiences, in a dose–response fashion. These results provide further support 
for the role of immunological components in the predisposition for psychosis and can 
serve as a base for further research.
Keywords: psychotic experiences, hallucinations, delusions, atopic disorders, asthma, eczema, allergic rhinitis, 
immune
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INTRODUCTION
During the past years, the role of immunological factors [e.g., 
microglia, major histocompatibility complex (MHC), and 
complement molecules] in the pathogenesis of psychosis is 
supported by an increasing amount of data (1, 2). Speculation as to 
how immunological processes may be linked to the development 
of psychotic experiences has been fueled by epidemiological 
studies on schizophrenia patients and their relatives, finding 
altered prevalence rates of various autoimmune diseases such 
as celiac disease, autoimmune thyrotoxicosis, psoriasis, and 
pernicious anemia (3). For instance, a large Danish register-
based study including 7,704 schizophrenia patients (and 192,590 
controls) found that the incidence of autoimmune disorders was 
higher both in patients and their parents (4). Notably, a history 
of autoimmune disorder was related to a 45% increase in risk of 
schizophrenia (4).
A similar association has been shown for atopic disorders (i.e. 
a familial group of allergic disorders including asthma, allergic 
rhinitis, urticaria, and atopic dermatitis). A cross-sectional 
study in Taiwan by Chen and colleagues (44,187 schizophrenia 
patients; 132,748 controls) (5) observed a 1.3-fold increased risk 
of concurrent asthma in patients as compared with individuals 
without any psychiatric disease. Similarly, Weber et al. reported a 
relative high prevalence of asthma and eczema in schizophrenia 
patients (6). A longitudinal Danish register-based study (n  = 
808,559) found that individuals diagnosed with an atopic 
disorder earlier in life had an increased relative risk of 1.45 of 
developing schizophrenia in adulthood (7); their results were 
mainly driven by asthma (relative risk = 1.59). Interestingly, 
this association has even been observed across the psychosis 
continuum, as a population-based longitudinal study (n = 6,784) 
showed that children diagnosed with eczema and/or asthma had 
an increased risk of developing psychotic experiences in their 
adolescence (odds ratio [OR] = 1.44) (8).
To extend these findings, we conducted the first large-scale 
population-based study of atopic disorders and psychotic 
experiences in both adolescents and adults. We investigated 
whether atopy (defined here as diagnosed asthma, eczema, and 
allergic rhinitis) increased the risk of psychotic experiences 
(defined as hallucinations in four sensory modalities and nine 




The current study is part of a larger cross-sectional, observational 
project conducted in the Netherlands, entitled “Zie ik spoken” 
[“Do I see ghosts?”; for methodology, see Linszen et al. (9)]. 
Inclusion took place through the project’s website (www.
zieikspoken.nl). The project was promoted between September 
2016 and May 2017 through national media channels and several 
events. The current study included participants aged 14 years and 
over.
Measures
Questionnaire for Psychotic Experiences
The Questionnaire for Psychotic Experiences (QPE) evaluates 
the presence and phenomenology of psychotic experiences, 
covering the full spectrum of hallucinations and delusions 
of any origin, severity, and duration (9, 10). As described by 
Linszen et al. (9), a self-survey version was used, addressing 
hallucinations in four sensory modalities and nine delusion 
subtypes. Screening questions evaluated the lifetime experience 
of a psychotic phenomenon. When answered affirmatively, 
follow-up questions regarding phenomenology were asked 
when this experience also occurred during the past week. 
Hallucinations were defined as a perception without a clear 
source from the environment. Delusions were considered as 
such if the participant reported being near to fully convinced 
of their truth. Prevalence rates were calculated by merging 
subtypes of hallucinations into one binary variable; a similar 
approach was used for the different delusion subtypes. The 
variable psychotic experiences were calculated by merging 
hallucinations and delusions.
Atopic Disorders
Screening questions addressed whether the participant ever 
suffered from asthma, eczema, or allergic rhinitis (described as 
hay fever) and, if so, whether the illness had been diagnosed by a 
doctor. Participants were divided into two different groups:
— Atopy: participants who reported one or more atopic 
disorder as diagnosed by a doctor [in line with previous 
register-based studies (5, 7)]. To evaluate a possible 
additive effect, the following subgroups were evaluated: 
1) one atopic disorder; 2) two atopic disorders; 3) three 
atopic disorders. We also examined effects of the three 
atopic disorders individually.
— Controls: participants without any atopic disorder, 
including those individuals who reported having one 
or more atopic disorders without being diagnosed by a 
doctor.
Procedure
Participants submitted their data via the website https://
zieikspoken.nl [11,601 entries, see flowchart in Figure 1; a detailed 
overview is provided by Linszen et al. (9)]. The Medical Research 
Ethics Committee of the University Medical Center Utrecht 
exempted this study from full review (local protocol number 
16-408/C). All participants (including underaged subjects) 
confirmed their participation via the study website. Participants 
filled out demographic data (e.g., age, sex, handedness, highest 
level of education), followed by the QPE hallucination items. 
After two recognition tasks [results described by De Boer (11)], 
participants could progress to the QPE items on delusions and 
the questions evaluating atopic disorders (6,857 valid entries). 
The current sample was restricted by age (≥14 years), resulting in 
6,479 participants with complete data.
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Statistics
Data were analyzed using IBM SPSS statistics (25.0). Demographics 
and prevalence rates of psychotic experiences were calculated 
for each group. Binary logistic regression was used to calculate 
ORs for psychotic experiences for the atopy (sub)group(s) as 
compared with the control group (age, gender, and years of 
education as covariates). We also evaluated the different subtypes 
of hallucinations and delusions as well as the individual atopic 
disorders (asthma, eczema, and allergic rhinitis).
RESULTS
Baseline Group Comparisons
About one third (37.8%) of the sample (n = 6,479) reported 
having atopic disorders as diagnosed by a doctor (see Figure 1 
and Table 1). Compared with the control group, the atopy group 
included fewer males (p ≤ .001). Percentage of individuals with 
psychotic experiences within the different groups are presented 
in Table 1.
Atopy and Psychotic Experiences
Individuals with one or more atopic disorders had a significantly 
increased risk of psychotic experiences as compared with those 
without such a diagnosis, with an OR of 1.26 (95% CI: 1.14–1.41; 
p < .001). A similar OR was observed for hallucinations (OR 1.27; 
95% CI: 1.14–1.42; p < .001), while the association with delusions 
bordered on significance (OR 1.21; 95% CI: 0.99–1.48; p = .054).
We also evaluated the possible additive effect of multiple 
atopic disorders (Figure 2). With each additional diagnosis of 
atopic disorder, the odds for psychotic experiences increased 
(Table 2). This pattern was also observed for hallucinations but 
not for delusions.
FIGURE 1 | Flow chart of the study.
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Hallucination and Delusion Subtypes
Compared to controls, atopy [≥ 1 diagnosed atopic disorder(s)] 
was associated with increased odds across all hallucination 
modalities with ORs ranging between 1.19 and 1.40 (OR for 
visual hallucinations was trend-level significant after Bonferroni 
correction), see Table 3. Atopy was not associated with any of the 
delusion subtypes.
Asthma, Eczema, and Allergic Rhinitis
Significant odd ratios for psychotic experiences were found for 
allergic rhinitis, asthma, and eczema as compared with those 
without atopic disorders (Table 3). The ORs were highest for 
allergic rhinitis (1.46), followed by asthma (1.32), and eczema 
(1.20). Results were similar for hallucinations, while the 
associations with delusions were not significant for any of the 













Male (%) 34.0% 27.3% 26.7% 22.9% 29.2% p < .001
Age,
mean (SD)
36.8 (15.7) 36.5 (14.5) 35.1 (14.5) 37.0 (14.3) 36.5 (13.9) p = .896
Years of education, 
mean (SD)
14.1 (2.1) 14.1 (2.1) 13.9 (2.1) 14.2 (2.0) 14.1 (2.0) p = .593
Psychotic 
experiences
33.6% 39.6% 41.6% 38.4% 42.5%
Hallucinations 31.2% 37.1% 39.2% 36.6% 39.9%
 Auditory 13.9% 18.2% 20.4% 17.5% 20.1%
 Visual 11.8% 14.0% 15.7% 13.2% 15.1%
 Tactile 10.1% 13.2% 13.4% 13.0% 14.1%
 Olfactory 9.0% 12.5% 13.4% 11.9% 13.3%
Delusions 6.5% 7.7% 8.5% 6.8% 7.2%
 Paranoia 1.7% 2.3% 2.8% 2.1% 2.1%
 Reference 1.6% 1.8% 2.3% 1.5% 1.7%
 Guilt 1.0% 1.5% 1.9% 1.6% 1.3%
 Control 0.9% 0.7% 0.9% 0.8% 0.7%
 Religious 0.5% 0.7% 1.0% 0.5% 0.5%
 Grandeur 1.5% 2.1% 2.3% 1.7% 2.0%
 Somatic 0.8% 1.4% 1.8% 1.4% 1.1%
 Capgras 0.4% 0.5% 0.3% 0.4% 0.6%
 Cotard 0.1% 0.5% 0.2% 0.2% 0.2%
aGender: χ2; age and years of education: Mann–Whitney U test. n, sample size; SD, standard deviation.
FIGURE 2 | Percentage of individuals reporting psychotic experiences, grouped by the number of diagnosed atopic disorders.
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individual atopic disorders (asthma bordered on significance, 
1.30). Regarding hallucination subtypes, all associations were 
significant except between asthma and tactile hallucinations and 
between eczema and visual hallucinations, which did not survive 
Bonferroni correction (Table 3). None of the delusion subtypes 
were significantly associated with asthma, eczema, or allergic 
rhinitis.
DISCUSSION
To our knowledge, this is the largest population-based study 
investigating the association between atopic disorders and 
psychotic experiences in an adolescent and adult sample. We 
observed an increased risk of psychotic experiences in individuals 
with atopic disorders as compared with those without, specifically 
for hallucinations. We found a dose–response relationship, with 
each additional atopic disorder diagnosis increasing the odds for 
psychotic experiences. This was also observed for hallucinations 
alone but not for delusions alone. Atopy was associated with 
hallucinations across all modalities, while the odds for delusions 
were not significant. These results did not appear to be driven 
specifically by allergic rhinitis, asthma, or eczema.
In comparison with findings of Khandaker and colleagues 
on childhood atopy and psychotic experiences in adolescence 
(8), we also found an increased risk of psychotic experiences 
in individuals with atopic disorders, both dichotomous and in 
a dose–response relationship. We replicated their finding that 
asthma and eczema are specifically associated with psychotic 
experiences, and extended these findings by also reporting higher 
odds for allergic rhinitis. In contrast to Khandaker (8), we found 
that atopy was associated with hallucinations across four sensory 
modalities, instead of auditory hallucinations alone (although 
the result for visual hallucinations was trend-level significant 
after correcting for multiple comparisons). While Khandaker 
found associations between atopy and two delusion subtypes 
(8), our results did not reach significance, which could be due to 
the limited number of reported delusion subtypes (percentages 
ranging between 0.1 and 2.8%).
Our findings are in accordance with previous studies 
reporting the high incidence of atopic disorders in schizophrenia 
patients by Chen and colleagues (5) and the increased risk of 
schizophrenia in individuals with atopic disorders by Pedersen 
et al. (7). Notably, both studies evaluated four different atopic 
disorders (asthma, allergic rhinitis, urticaria, and eczema) 
and found that their results were mainly driven by asthma. 
The high comorbidity between asthma and schizophrenia has 
also been reported by Weber et al. (6). This disorder-specific 
association was not evident in our sample, as the increased risk 
of psychotic experiences was observed for asthma, eczema, and 
allergic rhinitis. Moreover, our finding for allergic rhinitis does 
not corroborate the observation by Chen and colleagues (5), 
who observed that the risk for diagnosed allergic rhinitis was 
decreased in schizophrenia patients. However, Pederson et al. 
did report increased odds for allergic rhinitis but only when 
combined with urticaria and eczema (7).













1.20 p = .004
(1.06–1.35)
1.33 p = .003
(1.10–1.60)
1.80 p < .001
(1.34–1.42)
Hallucinations 1.18 p = .008
(1.05–1.34)
1.38 p = .001
(1.15–1.67)
1.85 p < .001
(1.38–2.48)
Delusions 1.26 p = .037
(1.02–1.57)
1.17 p = .376
(0.83–1.66)
0.93 p = .810
(0.51–1.70)
The group without (diagnosed) atopic disorders was used as reference (OR = 1.00). 
ORs adjusted for age, gender, and years of education (OR, 95% confidence interval). 
Raw percentages (noted for the 1 atopic disorder, 2 atopic disorders, and 3 atopic 
disorders groups): psychotic experiences 38.3, 40.3, and 49.2%; hallucinations 35.4, 
38.6, and 47.2%; delusions 8.0, 7.2, and 6.1% (also see Figure 2).
TABLE 3 | Associations between specific psychotic experiences and atopy, including the individual atopic disorders.
Atopy (n = 2,439) Asthma (n = 954) Eczema (n = 1,181) Allergic rhinitis (n = 1,252)
Psychotic experiences 1.26 p < .001 (1.14–1.41) 1.32 p < .001 (1.14–1.53) 1.20 p = .009 (1.05–1.38) 1.46 p < .001 (1.28–1.67)
Hallucinations 1.27 p < .001 (1.14–1.42) 1.34 p < .001 (1.15–1.55) 1.24 p = .002 (1.08–1.43) 1.47 p < .001 (1.28–1.68)
 Auditorya 1.36 p < .001 (1.19–1.57) 1.51 p < .001 (1.26–1.82) 1.31 p = .003 (1.10–1.57) 1.58 p < .001 (1.34–1.87)
 Visuala 1.19 p = .026 (1.02–1.38) 1.32 p = .006 (1.08–1.62) 1.10 p = .339 (0.91–1.34) 1.31 p = .003 (1.10–1.58)
 Tactilea 1.33 p < .001 (1.14–1.56) 1.29 p = .022 (1.04–1.60) 1.31 p = .010 (1.07–1.60) 1.47 p < .001 (1.21–1.78)
 Olfactorya 1.40 p < .001 (1.19–1.65) 1.51 p < .001 (1.21–1.87) 1.32 p = .009 (1.08–1.63) 1.53 p < .001 (1.26–1.87)
Delusions 1.21 p = .054 (0.99–1.48) 1.30 p = .051 (0.99–1.69) 1.07 p = .594 (0.83–1.40) 1.14 p = .304 (0.89–1.47)
 Paranoiab 1.31 p = .142 (0.91–1.87) 1.55 p = .059 (0.98–2.43) 1.22 p = .402 (0.77–1.94) 1.22 p = .395 (0.77–1.93)
 Referenceb 1.17 p = .422 (0.80–1.73) 1.45 p = .137 (0.89–2.38) 0.96 p = .876 (0.56–1.63) 1.07 p = .794 (0.65–1.76)
 Guiltb 1.60 p = .041 (1.09–2.53) 1.87 p = .031 (1.06–3.29) 1.71 p = .059 (0.98–2.99) 1.40 p = .264 (0.78–2.52)
 Controlb 0.87 p = .644 (0.49–1.55) 1.09 p = .828 (0.52–2.27) 0.93 p = .852 (0.44–1.95) 0.84 p = .646 (0.40–1.76)
 Religiousb 1.43 p = .262 (0.76–2.68) 2.02 p = .069 (0.95–4.29) 1.05 p = .913 (0.42–2.62) 0.91 p = .843 (0.37–2.26)
 Grandeurb 1.44 p = .060 (0.99–2.11) 1.60 p = .062 (0.98–2.63) 1.23 p = .437 (0.73–2.05) 1.39 p = .168 (0.87–2.24)
 Somaticb 1.67 p = .039 (1.03–2.70) 2.11 p = .013 (1.17–3.80) 1.74 p = .072 (0.95–3.19) 1.40 p = .289 (0.75–2.64)
 Capgrasb 1.24 p = .573 (0.59–2.61) 0.70 p = .567 (0.20–2.40) 1.07 p = .896 (0.39–2.93) 1.64 p = .252 (0.70–3.84)
 Cotardb 1.72 p = .395 (0.49–5.96) 1.72 p = .521 (0.33–8.92) 1.50 p = .634 (0.39–7.83) 2.05 p = .327 (0.49–8.64)
The group without (diagnosed) atopic disorders was used as reference (OR = 1.00). ORs adjusted for age, gender, and years of education (OR, 95% confidence interval).
aAlpha level was Bonferroni-corrected for hallucination subtypes (.05/4 = .0125)
bAlpha level was Bonferroni-corrected for delusion subtypes (.05/9 = .0056).
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In line with the continuum hypothesis of psychosis (12) 
describing psychotic symptoms along a continuous range (from 
isolated, nonclinical symptoms to those occurring in the context 
of psychotic disorders), our results contribute to the previously 
found associations between autoimmune disorders, atopy and 
schizophrenia (3–8). Current findings also corroborate previous 
genetic and biomedical studies that have indicated the involvement 
of immune-mediated pathways in the development of psychosis 
(1, 2). Genome-wide association studies have identified robust 
schizophrenia-associated risk loci involved in adaptive immunity 
(CD19 and CD20 B-lymphocytes) and the MHC region on 
chromosome six (1, 2, 13). The MHC region is best known for its 
involvement in antigen presentation and inflammatory mediators. 
It has also been suggested that asthma and schizophrenia may 
share genetic susceptibility (8, 14). Diverse immune alterations 
have been found in patients with a psychotic disorder, indicating 
inflammation of the central nervous system (1, 3). Cross-
sectional studies have linked inflammatory parameters in the 
blood, including C-reactive protein as well as interleukin-6 and 
interleukin-8, to severity of negative symptoms and cognitive 
performance in schizophrenia patients (15). Furthermore, as 
visualized with positron electron tomography, an increased 
number of activated microglia cells has been found in the brains 
of patients with recent-onset psychosis and those at ultra-high 
risk of psychosis (16, 17). Excessive microglial activity potentially 
provides a route by which an increased pro-inflammatory state 
in the brain may contribute to the gray matter thinning and 
synapse loss observed in schizophrenia patients (18, 19). Future 
research should further evaluate the complex interplay between 
mediating factors that are relevant for both psychosis and atopy, 
including genetics and environmental factors such as urbanicity 
and childhood trauma (20–23). Importantly, more insight in the 
immunological components of psychosis provides new leads to 
improve treatment options, with anti-inflammatory drugs being 
viewed as potential candidates for new augmentation therapies 
for at least a subset of patients (24).
Strengths and Limitations
A major strength of this study is the large number of participants. 
Online questionnaires are suitable to evaluate common phenomena 
and their risk factors in large samples, which can reveal subtle 
associations. Given the anonymity of participation, they are also 
suitable for stigmatized topics such as psychotic experiences.
One important limitation is that online surveys are more 
prone to participation bias and skewed population samples, 
which prompted us to include demographic variables as 
covariates in our analyses (25, 26). In addition, the choice to 
participate is influenced by individual interests and preferences 
that could have contributed to the relatively high percentages of 
hallucinations we observed. These percentages should hence be 
interpreted with caution [for an elaboration on this point, see 
Refs. (9, 11)]. Furthermore, similar to the Khandaker et al.’s (8) 
study, we based the presence of atopic disorders on these self-
reported data. Although we specifically asked whether these 
atopic disorders had been diagnosed by a doctor, these data 
could not be verified by making use of health records. A large 
systematic review by Pols et al. (27) compared self-reported 
prevalences from population-based studies with clinician-
diagnosed prevalences in general practice (children aged 0–18 
years, in the UK and the Netherlands) and concluded that the 
lifetime prevalence of asthma, eczema, and allergic rhinitis 
was lower in general practice. They also noted that individual 
estimates varied widely in both population-based and general 
practice studies. Our population-based lifetime prevalence rates 
of 14.7% for asthma, 18.2% for eczema, and 19.3% for allergic 
rhinitis were relatively low compared to those found by Pols et al. 
(asthma: population 19.1–35.6% vs. general practice 4.2–22.9%; 
eczema: population 16.5–27.1% vs. general practice 7.2–36.5%; 
allergic rhinitis: population 18.3–47.7% vs. general practice 
1.0–11.4%). Importantly, the ORs we found for atopic disorders 
increasing the risk for psychotic experiences were comparable 
with those reported by previous studies using national-register 
data (5, 7). We also performed additional sensitivity analyses, 
as 16.8% of our control sample reported an atopic disorder that 
was not diagnosed by a doctor, which may have introduced some 
false negatives. Excluding these individuals altogether (resulting 
in a sample of n = 5,800) gave similar findings with overall higher 
ORs (atopy versus controls: psychotic experiences OR 1.34; 
hallucinations OR 1.34; delusions OR 1.24). Our trend association 
between atopy and delusions now reached significance (p = .043).
As mentioned above, various factors could mediate the found 
associations between atopy and risk for psychotic experiences. For 
example, our dataset did not include measurements on urbanicity. 
However, two previous studies that further adjusted their estimates 
for degree of urbanization did not find a significant change in their 
results without this correction (5, 7). Furthermore, it is important 
to note that, although our findings were statistically significant, 
the percentage of reported psychotic experiences was only a few 
percent higher in participants with atopic disorders as compared 
with that in the control group. However, the effects were evident in 
a sample taken from the general population. Our findings indicate 
that atopic disorders are a risk factor even for the development of 
nonclinical psychotic experiences. This supports the proposition 
that the immunological pathway may constitute an important 
common underlying pathway in the development of psychotic 
experiences across the psychosis continuum, both in healthy 
individuals and in patients with a psychotic disorders (8, 12).
Conclusion
In the largest population-based study in adolescents and adults to 
date, we found that atopic disorders (asthma, eczema, and allergic 
rhinitis) increased the risk of psychotic experiences in a dose–
response fashion. These results provide further support for the 
involvement of immunological processes in the pathophysiology 
of psychosis.
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